Gupta, Mamta; Ansell, Stephen M; Novak, Anne J; Kumar, Shaji; Kaufmann, Scott H; Witzig, Thomas E
The mammalian target of rapamycin (mTOR) has emerged as an important therapeutic target for diffuse large B-cell lymphoma (DLBCL), as recent studies have demonstrated that 30% of relapsed patients respond to mTOR inhibitors. Why some lymphomas are resistant is incompletely understood. In the present study, we demonstrated that rapamycin inhibits mTORC1 in DLBCL lines and primary tumors but is minimally cytotoxic. Subsequent investigations revealed that rapamycin also activated eIF4E and the mTORC2 target Akt, suggesting a potential mechanism of rapamycin resistance. Furthermore, knockdown of the mTORC2 component rictor, but not the mTORC1 component raptor, inhibited rapamycin-induced Akt phosphorylation in lymphoma cells. Addition of the histone deacetylase inhibitor (HDI) LBH589 (LBH) overcame rapamycin resistance by blocking mTOR, thus preventing Akt activation. Further studies support the involvement of the protein phosphatase PP1 in LBH-mediated Akt dephosphorylation, which could be mimicked by knockdown of HDAC3. This is the first demonstration that a HDI such as LBH can overcome rapamycin resistance through a phosphatase that antagonizes mTORC2 activation. These results provide a mechanistic rationale for a clinical trial of a combination of HDI and mTOR inhibitors for DLBCL.
Diseases/Pathways annotated by Medline MESH:
Lymphoma, Large B-Cell, Diffuse
Document information provided by NCBI PubMed
Text Mining Data
Akt ⊣ raptor: " Furthermore, knockdown of the mTORC2 component rictor, but not the mTORC1 component raptor
rapamycin induced Akt
phosphorylation in lymphoma cells "
Manually curated Databases
No curated data.